|
Recent Developments |
|
14-MAY-15
Nectar Lifesciences (NecLife) has received ANVISA cGMP (current Good Manufacturing Practices) approval for Brazil for its Cephalosporin APIs manufacturing facility in Dera Bassi , Punjab. The regulatory authority concluded that the facility, systems and practices comply with ANVISA cGMP requirements.
03-MAR-15
Nectar Lifesciences, the fast-growing manufacture of generic pharmaceutical active pharmaceutical ingredients (APIs) and for... More.. |
| Business Profile |
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Brief Financials (in Rs. Mn.) | |
| Period ending (months) | 31-Mar-2016(12) | 31-Mar-2015(12) | 31-Mar-2014 (12) | | Net sales | 16763.21 | 16428.90 | 16377.69 | | Other Income | 56.30 | 199.98 | 116.28 | | Total Income | 16819.51 | 16628.88 | 16493.97 | | Cost of goods sold | 14016.97 | 13767.35 | 13495.44 | | OPBDIT | 2802.54 | 2861.53 | 2998.53 | | PAT | 592.84 | 662.63 | 620.80 | | Gross Block | - | - | - | | Equity capital | 224.26 | 224.26 | 224.26 | | EPS (Rs.) | - | - | 2.77 | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | - | 3.48 - 9.12 | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 16.7 | 17.2 | 18.2 | | Net margin (% of OI) | 3.5 | 4.0 | 3.8 |
|
|
Detailed Financials
|
|
|
|
|
